Health ยท GS2
Restriction on cough-and-cold combination for young children
One line
The government restricted manufacture, sale, and distribution of a chlorpheniramine maleate and phenylephrine combination for children below four years.
Summary
Young children are especially vulnerable to dosing errors and adverse effects from cough-and-cold medicines. Clear age restrictions, labels, prescriptions, and caregiver advice are core public-health safeguards.
PYQ pattern
UPSC may frame paediatric drug safety through regulation, labelling, pharmacovigilance, and health literacy.
Core notes
- Chlorpheniramine is an antihistamine; phenylephrine is used as a decongestant.
- An age-specific restriction does not mean the formulation is prohibited for every patient.
- Fixed-dose combinations need a sound therapeutic rationale and appropriate dosage.
- Regulatory notices require effective retail enforcement and public communication.
Prelims lens
- An antihistamine acts on histamine-related pathways.
- A decongestant aims to reduce nasal congestion.
- Children are not simply small adults for medicine dosing.
MCQ 1
The notified restriction applied to use in children:
- A. Below four years
- B. Below eighteen years in every case
- C. Only above sixty years
- D. Of all ages without distinction
Reveal answerHide answer
A
The PIB release specified children below four years.
MCQ 2
Which statement is correct?
- A. Paediatric dosing can ignore age and weight.
- B. An age-specific restriction is not necessarily a universal ban.
- C. Fixed-dose combinations never require review.
- D. Labels have no safety role.
Reveal answerHide answer
B
The restriction applies to a defined age group and formulation.
Mains
Question, 10 marks, 150 words: What makes medicine regulation for children a distinct public-health priority?
Approach:
- Explain developmental and dosing differences.
- Discuss evidence, formulations, labels, and caregiver behaviour.
- Note enforcement and pharmacovigilance.
- Suggest clear warnings and clinician education.